Delivery Order SPE2DR25D1103-SPE2DR26FD730
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for Ozempic (0.25-0.5 mg/dose) pens in 3ml quantities, valued at $5,043.18. This is a firm fixed-price delivery order with an ultimate completion date of June 2, 2025, representing a non-competitive set-aside award. The order will be fulfilled at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and serves as a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens in 3ml vials, with a ceiling value of $16,813.02. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of September 26, 2025. The order is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml) with a ceiling value of $7,769.38. This firm fixed-price delivery order, with an ultimate completion date of November 7, 2025, represents a competitive award with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) with a ceiling value of $1,136.92. This is a firm fixed-price delivery order with an ultimate completion date of July 31, 2025, and represents a non-set-aside competitive award. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location, where the company maintains its corporate headquarters and serves as...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $17,272.62 for Ozempic 0.25-0.5 mg/dose pens (3mL) on November 12, 2025, with an ultimate completion date of November 13, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $4,090.63 delivery order on November 3, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml) with an ultimate completion date of November 4, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed price pricing and is classified as a child contract under AmerisourceBergen's larger federal contracting vehicle. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, the location of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Ozempic 0.25–0.5 mg/dose pens (3 mL) with a ceiling value of $3,607.20. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for completion by September 29, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) with a ceiling value of $9,153.24. This competitively awarded, firm fixed-price contract represents a single delivery order with an ultimate completion date of August 22, 2025. The order will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) with a ceiling value of $1,879.98. This is a firm fixed-price delivery order with an ultimate completion date of September 26, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on September 19, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) with a contract ceiling value of $10,361.60. This is a firm fixed-price delivery order with an ultimate completion date of September 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was made through competitive bidding with no set-aside designation. This...
- SPE2DR25D1103Indefinite Delivery Contract
- SPE2DR25D1103-SPE2DR26FD730Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml) with a ceiling value of $10,555.27. This firm fixed-price delivery order, which is scheduled for completion by November 4, 2025, represents a competitive award with no set-aside designation. The award was fulfilled by AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania, the company's headquarters and primary place of performance for this contract. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999.99 billion and extending through December 2026. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen supplies a broad portfolio of medications and medical supplies to support military healthcare programs and other federal medical procurement needs. The company's extensive federal contract portfolio with the DLA demonstrates its capability to meet competitive procurement requirements across multiple therapeutic domains, including diabetes medications such as Ozempic, enabling the company to support the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.6k | 11/3/25 |